Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Neuromyelitis optica
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVENT
  • Sponsors Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 18 Apr 2024 Results assessing efficacy and safety of eculizumab and ravulizumab from PREVENT and CHAMPION-NMOSD trils presented at the 76th Annual Meeting of the American Academy of Neurology 2024.
    • 08 Apr 2024 According to an Alexion Pharmaceuticals media release, company will present oral presentation highlighting results from this trial at the American Academy of Neurology (AAN) Annual Meeting in Denver, CO, 13 to 18 April 2024
    • 18 Oct 2023 According to an AstraZeneca media release, Soliris (eculizumab) has been approved by the National Medical Products Administration (NMPA) in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top